[ad_1]
[GCN Green Cross] announced on the 31st that the operating profit in the second quarter (April – June) of the consolidated financial statements was provisional totaling 13.3 billion won, 61.5% lower than the same period the previous year. last year.
The turnover for the same period was 341.8 billion won, up 3.5% over the same period last year.
GC Green Cross domestic sales increased 1.7% year-over-year and foreign sales increased 7.2% year-over-year due to increased sales of products in Latin America.
The increase in sales is due to the increase in research and development costs, but the operating profit decreases
A GC Green Cross official said: "In the second quarter , research and development expenses increased by 18.9% "Despite the decline in operating income, we expect to maintain a dynamic R & D investment base by investing more than 30% in R & D. "This year," he said, "it's an expression of willingness to stop digging up future food."
GC Green Cross believes blood products and vaccines should reach profitability on a global scale as the domestic market becomes saturated.
[ad_2]
Source link
